Member Info for MrRipley

Alderban do you realise we have funding until next year? And Myles just tried to explain how they might get funding also if a raise was needed it would be at a time when we have a lot of AVA6000 data which if positive would be a raise at a much higher SP

LSE, any chance of removing this duplicate (Coolfree) account? It was probably made by mistake I’m sure. Thanks.

Exactly PL. There is no other benefit to stopping posting history other than to prevent obvious bashers being outed.

NDN, are toy still randomly targeting nurses on Twitter to abuse? Put a lid on it mate, you’re boring.

NDN exploding in 3-2-1.

Great post Myles.

And agreed PL75. Funny how the post history function has been turned off by the way. Who’s arse are they covering there?

Move to ODX hahahahahaha.

Oh really yuri. Give us all a quick breakdown of market ops for PreCision, TMAC and a basic outline of the AVA6k trial. You seem really knowledgeable. Then I’d like an outline of the Daewoong deal, any funding it has and when we can expect the first milestone payment from LG. Thanks.

Gene, success rates of clinical trials for what kind of drug? How many phases will our trial have and what are we trialing?? Can’t wait for you both to educate us all here.

Come one, come all, brilliant minds of the Avacta BB. I’ve never seen such an all knowing bunch. Here ye here ye cast your eyes asunder and solve the unsolvable with your superior minds; I present to you the conundrum that is perpetual motion. I’ll leave this here. Im sure you’ll all argue over the best way to go about it. But I’m certain, in you’re growing excellence, that you can do it……

https://en.m.wikipedia.org/wiki/Perpetual_motion

I’m all knowing was meant to be I’m not saying. But i am all knowing that a lot here know absolutely nothing.

No you’re right.

AVA6000
LG deal
Daewoong Deal
Cash in the bank for the next year
Proof of concept with Affimers.
Point deal.
Multiple licensing deals.
Milestone with LG
$7.8m dollar funding for Daewoong partnership.

Absolutely nothing except Als new house, and whole 350k or so worth I’d shares sold for a company he’s built into a clinical stage biotech, increased the share price from 18p to 290 (everyone could have sold) which is now still 400% of what it was, and fought against a corrupt validation set up by the UKGov that prevented our test being available way before omnicron was ever a variant.
I’m not saying he’s done well here with this shambles today, but my goodness to say he’s done nothing is unbelievable. It’s also telling how much everyone here is struggling with the science, yet everyone knows best. And I’m all knowing best everyone is in a panic and angry. I’m not saying people can’t be angry, but if everyone knows so much and is so business and science savvy then how come you aren’t all CEOs of a company who managed to secure Affimers, TMAC and PreCision, or rather how come you all need to invest to make it, why aren’t you all using you’re incredible minds to create your own start ups? Quick poll, how many here are sat on or are planning to spend time on their own private yacht in the Caribbean? God I wish I was as clever as a lot of you are. It’s so impressive. I’m very impressed.

We were already told before today that the test contained an antibody at the control line. It was in one of the presentations with RainAl (rainman reference due to he fastidiousnessnesssaa) anyway. I’ll trawl through them to find it right after I manage to make myself care enough…. Which will be never.

By high…..

I mean 85p to show a 10% or so drop on open and get a bit more panic out there

72% for Avct sorry. Not that it matters really. ****ed is ****ed.

Avacta is around 77% down from 2.90.
ODX is around 83% down from 125.

Avacta has AVA6000 and a host of other ops and partnerships and will one day come good. (Talking years here now)
ODX is relying on serious sales during this pandemic which are extremely unlikely to appear. Beyond the pandemic they have food intolerance tests. Most people know they’re intolerant as toddlers when a rash appears or they fart themselves near to death.

Nobody with a brain is jumping to ODX

Ava6000 isn’t Affimer based pal.

“Ex spandex deal with LG (inc milestone met)”

And once it becomes with spandex we’ll be £300 ex chi-nah.

Was meant to say expanded.

Tkevin.

Since the start of the pandemic.
Ava6000 has gone from pre clinical to clinical
We have funding until 2023
We have market exposure.
Proven Affimers via BAMS and Elisa (LFT to a degree)
Expanded deal with Daewoong (inc 7.8m raised in funding without dilution)
Ex spandex deal with LG (inc milestone met)
Licensing deal with Point.
Other licensing deals.

Also we weren’t 8p. It was 18p. Only 125% wrong.

Other than that yeah, it’s exactly the same.

We’re now 67 or so % down from highs with no AffiDX on sale at all.

Still not as down as ODX. No test, no future beyond covid.
NCYT. No LFT. PCR testing heading to a close. In court vs the DHSC.
BRH. Biggest con on AIM outside of Syme.
GDR. Actually think they’ll get HUA this century.
ABDX. Actually feel sorry for these. We dragged them down with us.

So any talk of money moving to those shares when Avacta has so much beyond covid is folly. A bad day. Time to switch off for a while.

Good luck to all here. See you in the funny papers.

Here’s how I would have done it.

The test still detects omnicron but the T line is faint (it actually is less clear, me and my partner noticed this a few weeks back, but it’s still very clear) so the actual test performance isn’t compromised. So if I were CEO I would have ordered a change to the antibody, made the change and then told the market. But why remove it if it’s still working as a diagnostic tool? It’s like recalling a car because the ignition light has gone slightly less bright than it should be but the rest of the car works fine. It’s not critical to the performance of the car. The T line hasn’t vanished, it’s just not as solid red as it was.
Anyway. It is what it is. And what it is is a really poor commercial decision by a scientist who really shouldn’t be involved in the commercial side of the business.

As I’ve stated… discount the LFT. It’s not going to sell in great numbers, it’s being used by AL to showcase Affimers and nothing more. If you still have dreams of huge sales you’re a dreamer.

It’s all AVA, TMAC, partnerships, etc now. I’m revising my diagnostics GoFundMe page to and OH****Me page and the price target from 1bn to 1 franc and a packet of cheese and onion Golden wonders

Thanks Gadgie

“The near-term opportunities for AffiDX, while difficult to accurately quantify at this stage, are clearly attractive; however, we expect the Therapeutics pipeline to drive greater long-term value with the Affimer and pre|CISION platforms having the potential to generate an extensive pipeline of prospective products. Our Avacta valuation is £710m (280p/share), with the Diagnostic opportunities representing £133m and the Therapeutic pipeline rNPV £559m”

Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.”

So even without diagnostics we should be over £2

?

https://m.youtube.com/watch?v=NGW-tV4eQaA